Edgestream Partners, L.P. Acadia Pharmaceuticals Inc Transaction History
Edgestream Partners, L.P.
- $3.48 Billion
- Q2 2025
A detailed history of Edgestream Partners, L.P. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 111,144 shares of ACAD stock, worth $2.33 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
111,144
Previous 159,108
30.15%
Holding current value
$2.33 Million
Previous $2.64 Million
9.27%
% of portfolio
0.07%
Previous 0.09%
Shares
9 transactions
Others Institutions Holding ACAD
# of Institutions
351Shares Held
164MCall Options Held
811KPut Options Held
334K-
Baker Bros. Advisors LP New York, NY42.9MShares$898 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$320 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$253 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$188 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$129 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.39B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...